drugset / Trial / NCT00240656
Spironolactone Combined With Captopril and Carvedilol for the Treatment of Pulmonary Arterial Hypertension
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether a larger dose of the aldosterone antagonist spironolactone combined with an ACE inhibitor (captopril) and a beta-blocker (carvedilol) is effective in reverse pulmonary artery remodeling in patients with pulmonary arterial hypertension (PAH)secondary to congenital heart disease
Timeline
- Start
- 2005-10
- Primary completion
- —
- Completion
- 2006-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Captopril | Small molecule | — | — |
| Subject | Carvedilol | Other / unclassified | — | — |
| Subject | Spironolactone | Small molecule | — | — |